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Highlights 
 
 Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. 
 Similar decreased TAC levels were found in beta-thalassemia major and trait. 
 No relationship between TAC and disease severity could be established. 
 The possible interference of uric acid and bilirubin must be taken into account. 
 Uric acid-independent TAC might be the better approach to evaluate antioxidant status. 
 
 
Abstract 
Total Antioxidant Capacity (TAC), a biomarker measuring the antioxidant potential of body fluids, 
including redox synergistic interactions, is influenced by the presence of products of catabolism 
such as bilirubin (BR) and uric acid (UA). Hyperuricaemia and increased BR levels were observed 
in thalassemia. In order to evaluate the differences in TAC values between thalassemic patients and 
healthy subjects, we performed a systematic review and meta-analysis of case-control studies. After 
the exclusion of data deemed unsuitable for meta-analysis inclusion and a study imputed of bias by 
Trim-and-fill analysis, mean difference (MD) and confidence intervals 95% (CI 95%) were 
calculated by the random effect model for beta-thalassemia major (BTM) (1351 subjects: 770 
thalassemic and 581 controls, from 15 studies) and Trait (BTT) or Hemoglobin E (BTE) (475 
subjects: 165 thalassemic and 310 controls, from 5 studies). Despite the differences in clinical 
symptoms and severity, similar decreased levels of TAC were found in BTM [MD -0.22 (-0.35 -
0.09) p<0.001] and BTT or BTE [MD -0.22 (-0.44 -0.01) p<0.05]. In conclusion, UA and BR 
interference on TAC suggests that corrected TAC and in particular the UA-independent TAC, 
considering the prominent influence of UA, might be the better approach to evaluate body 
antioxidant status. 
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1. Introduction  
Beta-thalassemia major (BTM) is the most prevalent type of beta-thalassemia (BT), comprising also 
thalassemia Trait (BTT or minor), thalassemia Intermedia (BTI) and Hemoglobin E thalassemia 
(BTE) [1]. BTM requires regular transfusion therapy to maintain hemoglobin levels of at least 9 to 
10 g per deciliter and to reduce hepatosplenomegaly due to extramedullary hematopoiesis [1]. Both 
haemolysis and transfusional iron overload cause excessive generation of free radicals (through the 
Fenton reaction), and, consequently, iron-chelation therapy is largely responsible for doubling the 
life expectancy of patients with BTM [1]. Excessive generation of free radicals can cause oxidative 
damage to biological macromolecules such as DNA, lipids, carbohydrates and proteins [2]. In beta-
thalassemia, malonyldialdehyde (MDA; a by-product of lipid peroxidation) levels correlate 
positively with serum iron and oxidative stress levels were shown to largely normalize in response 
to oral therapy with antioxidants [1]. Oxidative stress is the imbalance between reactive oxygen 
species (ROS) and antioxidant defense [3]. ROS is a collective term used by biologists to include 
not only oxygen-derived radicals, such as the superoxide anion, hydroxyl radical, peroxyl, alkoxyl 
and oxides of nitrogen, but also some derivatives of oxygen that do not contain unpaired electrons, 
such as the hydrogen peroxide and the hypochlorous acid produced by inflammatory cells [3]. The 
human body has a complex strategy for countermanding the deleterious effects of ROS, which 
include both antioxidative and repair mechanisms [4]. Antioxidant defenses of the body are 
composed of enzymes, such as superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidase (GPX) and low molecular weight antioxidants, including glutathione (GSH), uric acid 
(UA), bilirubin (BR), thiols (SH), vitamin E (Vit. E), ascorbic acid (Vit. C), carotenoids and other 
nutritional antioxidants [4].  
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Synergistic interactions between antioxidants, in part involving antioxidant regeneration, need to be 
taken into account in order to properly assess antioxidant status in vivo. Total Antioxidant Capacity 
(TAC), defined as the moles of oxidants neutralized by one litre of plasma [5], is a biomarker 
measuring the antioxidant potential of body fluids, including redox synergistic interactions [5].  
Over the past decade, a large number of assays and kits for the measurement of TAC in biological 
matrices have been developed and the most commonly used assays, their basic features, and their 
points of strength and weakness, have been extensively discussed in several comprehensive reviews 
[6-9]. 
The more commonly used methods are the Ferric Reducing Antioxidant Potential (FRAP) and 
Trolox Equivalent Antioxidant Capacity (TEAC) within the single electron transfer (SET)-based 
assays and the Total-radical Trapping Antioxidant Parameter (TRAP) and the Oxygen Radical 
Antioxidant Capacity (ORAC) within the hydrogen atom transfer (HAT)-based methods [4, 6-9]. 
Although the discussion on the method used for determining TAC is not a central issue in the 
current study, it must be stated that the results obtained from FRAP and ORAC measurements 
correlate well, but not between the aforementioned methods and TEAC [10]. On the other hand, the 
copper(II) reduction assay (CUPRAC) does significantly correlate with FRAP and TEAC, but not 
with the 1,1-diphenyl-2-picrylhydrazyl assay (DPPH) for plasma samples [11]. Despite the different 
features of the TAC methods, their common major bias is that they are influenced by the presence 
of products of catabolism, such as bilirubin (BR) and uric acid (UA) [10]. Both hyperuricaemia [12] 
and increased BR levels [13] can be observed in thalassemia.  
The objective of this meta-analysis was to evaluate the differences in TAC values between 
thalassemic patients and healthy subjects. To this aim, a systematic review of the available literature 
and meta-analysis of included case-control studies was conducted in this work. 
 
2. Methods  
2.1 Literature Screening 
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We performed a systematic search in the MEDLINE, EMBASE, ProQuest and Google scholar 
databases for relevant literature up to September 2015 with the search string: [thalassem* AND 
(antioxidant* OR ox*)]. The flowchart outlining the process of search criteria and study selection is 
shown in Figure 1. 
 
2.2 Study Selection 
Studies that met the following criteria were included for meta-analysis: (1) The outcome had to be 
thalassemia; (2) at least two comparison groups (case vs. control group); (3) studies in which the 
plasma TAC levels were expressed as millimolar (mM). Exclusion criteria included: (1) Review 
articles; (2) in vitro studies; (3) animal models; (4) patients with other diseases. Trials were initially 
identified through title or abstract. Study selection was performed independently by two reviewers 
(H.M. and M.P.) to ensure uniformity. Discrepancies were resolved by discussion with a third 
reviewer (I.P.). 
 
2.3 Data Extraction 
The data extracted from each study included the first-author’s name, year of publication, country of 
the study performed, ethnicity, subject characteristics, type of BT, comorbidities, method of 
evaluation of TAC and other markers of plasma redox status. For each study with more than one 
beta-thalassemic group, we divided the control group evenly according to the number of disease 
groups [14]. When the data were presented as standard error of means (SEM), standard deviation 
(SD) was obtained by multiplying SEM by the square root of the sample size [14]. Data extraction 
was performed independently by two reviewers (H.M. and G.D.) to ensure uniformity. 
Discrepancies were resolved by discussion with a third reviewer (I.P.). 
 
2.4 Statistics and Analysis 
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Meta analysis was performed with MIX software (BiostatXL) [15]. Mean difference (MD) and 
confidence intervals 95% (CI 95%) were calculated by the random effect model (DerSimonian & 
Laird) for continuous data. Statistical heterogeneity was assessed by using the 2 statistic and 
Egger’s weighted regression statistics [14]. Symmetry or asymmetry of funnel plots and trim-and-
fill sensitivity analysis were used to determine the presence of publication bias [14]. 
 
3. Results  
3.1 Data Extraction  
Figure 1 depicts the flow of studies in this review and the four-phase diagram of meta-analysis 
according to the PRISMA Statement [16]. After exclusion of irrelevant references, a total of 27 
studies [17-43] were identified as suitable and were retrieved for complete review. In general, 
normally distributed data are given as mean ± SD and not normally distributed variables as medians 
(25–75 percentiles). Therefore, we excluded studies with data presented as medians [17-19], as well 
as one study in which results were presented exclusively in figures [20]. In addition, considering 
that TAC ranges between 10-3 M and 10-4 M, we also excluded studies that reported TAC values of 
10-2 M [21], 10-6 M [22] and 10-9 M [23]. The remaining 19 studies met our inclusion criteria and 
were suitable to provide data for the analysis (Figure 1). With regard to the study by Ozdemir et al. 
[38], we only included the non supplemeted group in the analysis, but retained the N-acetylcysteine 
(NAC) and Vit. E-supplemented groups for the discussion. Due to the differences in clinical 
symptoms and severity of the disease [1], we performed the analysis separately for BTM and BTT, 
BTI or BTE. Since there were 8 studies with different disease groups, 28 datasets from 19 studies 
were analyzed, of which 21 on BTM and 7 on BTT, BTI or BTE.  
Concerning BTM, the number of subjects was 1379, of which 778 thalassemic and 591 controls. 
Conversely, 493 subjects (173 thalassemic and 320 controls) were analyzed for BTT, BTI or BTE. 
 
3.2 Publication Bias  
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Trim-and-fill analysis and Egger’s test were performed to estimate the publication bias of the 
studies. Funnel plots showed asymmetric distribution of results (Figure 2). The drawback in using 
the funnel plot is that it is purely subjective. Therefore, trim-and-fill analysis was used to estimate 
how many studies are in the asymmetric part. In particular, Trim-and-Fill analysis creates a funnel 
plot that includes both the observed studies and the imputed studies. Trim-and-fill analysis showed 
no publication bias for BTM (Figure 2A) and a study imputed of bias for BTT, BTI or BTE (Figure 
2B). The imputed study resulted from work by El Gendy et al. [28]. This dataset did not involve 
BTI patients, but BTT subjects [28]. Furthermore, this study reported TAC levels that were 
approximately 2-fold higher for healthy subjects compared to the majority of the other reviewed 
studies. Therefore, after the exclusion of this study involving BTI, BTT and BTM patients, a second 
analysis was performed for both BTM (1351 subjects: 770 thalassemic and 581 controls from 20 
datasets) and BTT or BTE (475 subjects: 165 thalassemic and 310 controls from 5 datasets), as 
shown in Figure 1. Low statistical heterogeneity was found for BTM (2 = 0.08, Egger intercept 
−1.59, p > 0.05) and BTT or BTE (2 = 0.07, Egger intercept −9.15, p > 0.05). Funnel plots showed 
symmetric distribution of results and Trim-and-fill analysis showed no publication bias (Figure 2C 
and 2D).   
 
3.3 Meta-Analysis  
Decreased levels of TAC were found in both BTM [MD -0.22 (-0.35 -0.09) p<0.001] and BTT or 
BTE [MD -0.22 (-0.44 -0.01) p<0.05] (Table 1). 
Table 1 shows the results of each study separately and the contribution of each study to the overall 
results of meta-analysis for BTM and BTT. Furthermore, we presented the effect of accumulating 
the results when each study is added (Table 1).  
Despite the differences in clinical symptoms, disease severity and the reported lower TAC values in 
patients infected by transfusion (HIV+ and/or HCV+) [17], our study found that the MD between 
thalassemic and control subjects was similar for BTM and BTT or BTE (Table 1).  
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3.4 Characteristics of Selected Studies 
Characteristics of the included studies are shown in Table 2.  
TAC was measured by TEAC in the majority of the studies (n=13), but also TRAP (n=2), FRAP 
(n=1) and ELISA kit (n=1) were used. Furthermore, Labib et al. [39] referred to a method that used 
UA as a standard [44] instead of the more commonly used Trolox [6-9]. Despite these 
methodological differences, TAC was lower in patients versus controls in the majority of the 
studies, regardless of the assay used and of the ethnicity of the subjects (Table 2). However, 
unchanged or increased levels of TAC were also reported (Table 2). 
Mean age of patients with BTM ranged between 7.54.3 [27] and 21.610.5 [25], whereas mean 
age of subjects with BTT or BTE ranged between 21.20.6 [42] and 36.67.9 [39] (Table 2). The 
difference in mean age was probably due to the fact that BTM is characterized by severe anemia 
(requiring regular transfusions beginning in infancy), severe iron overload (requiring chelation 
therapy), splenomegaly and bone disease (depending on the efficacy of the transfusion therapy), 
whereas other types of BT could range from asymptomatic, with mild or no anemia and variable 
microcytosis, to severe [1]. Some of the reviewed studies conducted on BTM reported that a 
number of patients exhibited clinical complications or comorbidities, such as cardiovascular 
diseases (CVD), insulin dependent diabetes mellitus (IDDM), or were hepatitis C virus positive 
(HCV+) and/or human immunodeficiency virus positive (HIV+) (Table 2).  
Sixteen out of nineteen studies also measured other markers of redox status (Table 2). 
Increases of UA and BR were measured in BTM, but also unchanged levels of UA were found 
(Table 2). Despite the increased TAC and the direct correlation between TAC and BR or UA found 
by Bazvad et al. [9], other studies reported decreased TAC irrespective of UA and/or BR increases 
(Table 2). On the other hand, when TAC, Vit. C, Vit. E and carotenoids were measured in the same 
study, it turned out that there was a clear accordance between the antioxidant concentration and 
TAC (Table 2). Furthermore, in the majority of the studies on BTM and in all studies on BTT, the 
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markers of oxidation [Total Oxidant Status (TOS), carbonyls, peroxides (ROOH), MDA or 
thiobarbituric acid reactive substances (TBARS)] were associated with decreased TAC (Table 2). 
Conversely, contrasting results were obtained from antioxidant enzymes evaluation, probably due to 
the great variability of the various samples analyzed, such as erythrocytes (red blood cells, RBC) 
[30, 33, 34, 42], peripheral blood mononuclear cells (PBMC) [34] or serum [24]. For example, 
Kuppusamy et al. [34] reported that CAT activity was increased in PBMC, but not in RBC.  
 
4. Discussion  
Overall, our meta-analysis indicates that TAC is decreased in thalassemic patients versus healthy 
subjects (Table 1). However, despite the differences in clinical symptoms, similar decreased levels 
of TAC were found in BTM and BTT or BTE groups (Table 1), indicating that TAC is not related 
to disease severity. To understand this result several considerations should be made.  
Since the first study that evaluated TAC in BTM [35], it has been argumented that blood 
antioxidants such as UA and BR, known to contribute significantly to the plasma TAC value, may 
be expected to increase in thalassemia patients because of haemolysis and liver damage.  
Among the reviewed studies measuring TAC, UA and/or BR (Table 2) 40% (2/5) reported increases 
of both TAC and UA, whereas increased TAC and BR levels were observed in one out of six 
studies, concurrently with high UA levels [26]. 
UA provides 60-80% of TAC in plasma [45, 46] and it has been reported that TAC is mainly related 
to the UA concentration of plasma, urine and saliva [47-49]. Therefore, due to the dominating 
influence of UA in biological fluids, it has been suggested [49] that TAC loses its sensitivity 
considerably, since UA obscures the influence of those compounds with antioxidant capacity that 
are present at lower concentrations, and that the determination of the UA-independent TAC appears 
more meaningful. Therefore, methods for UA-independent TAC have been proposed that utilize the 
uricase-reaction [50] or by using a corrected TAC (TACcorr); the calculated parameter that 
represents the fraction of circulating antioxidants after the elimination of the interference by 
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endogenous antioxidants [49, 51]. However, uricase methods might be inherently biased because of 
the mechanism of the action of uricase, which generates one molecule of H2O2 for every molecule 
of UA [52]. Therefore, TACcorr might represent the better approach. The plasma level of UA is 
regulated by renal function [53]. In this context, plasma TAC values of hemodialyzed patients were 
high [51] compared to those of control individuals before dialysis and during dialysis these elevated 
values decreased due to UA and BR decreases. In contrast, while initial TACcorr was significantly 
lower than that of controls, it increased during the dialysis procedure and reached normal values at 
the end of dialysis.  
Hamed et al. [32] reported glomerular and tubular dysfunctions in BTM patients. However, none of 
the reviewed studies reported data on TACcorr and only two studies reported data on calculated TAC 
(TACcal). In these studies [26, 36], TACcal was determined according to the relative activity of 
major endogenous plasma antioxidants of the different methods used [i.e. 2,2’-azinobis-3-
ethylbenzothiazoline-6-sulfonic acid (ABTS) and TRAP]. However, in the study by Mastroiacovo 
and co-workers [36], TACcal was biased by the inclusion of vit. E (an exogenous antioxidant) in the 
calculation.  
Vit. C, vit. E and beta-carotene, when measured, were decreased in 75% of the case-control studies 
on BTM (Table 1). It has been suggested that the decreased TAC could be the result of the marked 
decrease in vitamin levels [35]. In this context, in the study by Ozdemir et al. [38], children with 
BTM and supplemented with NAC (10 mg/kg/day) or Vit. E (10 IU/kg/day) had higher TAC and 
lower TOS after 3 months of treatment compared to before the start of treatment. Therefore, despite 
the fact that TAC was not related to disease severity, it might still be a valid marker of antioxidant 
status during antioxidant treatment in BT. 
The major limitation of this meta-analysis is that the number of studies that contributed substantial 
data to the meta-analysis was limited. Therefore, we did not perform a subgroup analysis for 
treatment and we could not adequately investigate sex and age differences.  
As a consequence, a number limitations should be allowed for. 
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First of all, it has been reported that ferritin was higher in older patients [35] and negatively 
correlated with TAC [29], whereas Bazvand et al. [26] found no correlation between age and TAC. 
Secondly, the current "normal" range set for hyperuricaemia is gender-specific [54-57] and increase 
in serum UA levels may also be due to dietary factors, such as increased intake of purine [58], 
alcohol [59] and fructose [60]. None of the reviewed study included data regarding the food 
frequency questionnaire and only one study reported data of men and women separately [26]. In the 
latter study [26], TAC and BR levels in male patients were significantly higher than in females. 
Again, some of the reviewed studies conducted on BTM reported cases of splenectomy [27, 29, 32, 
35, 38]. Both decreased [29] and unchanged [34] TAC levels were reported in splenectomized 
compared to nonsplenectomized patients with BT. 
Finally, the effect of chelation therapy should be taken into account. Thalassemic patients not 
receiving or on irregular chelation therapy had significantly lower TAC, irrespective of serum UA 
[32] and BR [34]. On the contrary, although Hamed et al. [32] reported glomerular and tubular 
dysfunctions in patient with and without chelation, renal damage was higher in patients receiving 
chelation therapy (deferoxamine).  
In summary, many factors affect TAC values and consequently these must be taken into account 
when interpreting TAC values. 
 
5. Conclusion  
Our meta-analysis suggests that, although thalassemic patients had lower TAC compared to healthy 
subjects, no relationship to disease severity could be established, probably due to UA and BR 
interference. In particular the prominent influence of UA suggests that UA-independent TAC would 
represent a significantly better approach when evaluating the antioxidant status of the body. 
 
Conflict of Interests 
The authors declare that there is no conflict of interests regarding the publication of this paper. 
 12 
Acknowledgements 
We thank Claudio Andrew Gobbi for English review of the manuscript. I.P. was supported by the 
grant of the Italian Ministry of Agricultural, Nutritional Policies and Forestry (MiPAAF - 
MEDITO). 
 
 
 
 
References  
[1] Rund D, Rachmilewitz E. Beta-thalassemia. Rund N Engl J Med. 2005; 353(11):1135-46. 
[2] Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. 
Biochem J. 1984;219(1):1-14.  
[3] Halliwell B, Cross CE. Oxygen-derived species: their relation to human disease and 
environmental stress. Environ Health Perspect. 1994;102 Suppl 10:5-12. 
[4] Serafini M, Miglio C, Peluso I, Petrosino T. Modulation of plasma non enzimatic antioxidant 
capacity (NEAC) by plant foods: the role of polyphenols. Curr Top Med Chem. 
2011;11(14):1821-46 
[5] Niki E. Assessment of Antioxidant Capacity in vitro and in vivo. Free Radic Biol Med. 
2010;49(4):503-15. 
[6] Bartosz G. Non-enzymatic antioxidant capacity assays: limitations of use in biomedicine. Free 
Radic Res. 2010;44(7):711-20.  
[7] Knasmüller S, Nersesyan A, Misík M, Gerner C, Mikulits W, Ehrlich V, Hoelzl C, Szakmary 
A, Wagner KH. Use of conventional and -omics based methods for health claims of dietary 
antioxidants: a critical overview. Br J Nutr. 2008;99 E Suppl 1:ES3-52. 
[8] Pinchuk , Shoval H, Dotan Y, Lichtenberg D. Evaluation of antioxidants: scope, limitations 
and relevance of assays. Chem Phys Lipids. 2012;165(6):638-47. 
 13 
[9] Dilis V, Trichopoulou A. Assessment of antioxidants in foods and biological samples: a short 
critique. Int J Food Sci Nutr. 2010;61(5):441-8. 
[10] Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant 
capacity of human serum. Clin Chem. 1998;44(6 Pt 1):1309-15. 
[11] Campos C, Guzmán R, López-Fernández E, Casado A. Evaluation of the copper(II) reduction 
assay using bathocuproinedisulfonic acid disodium salt for the total antioxidant capacity 
assessment: the CUPRAC-BCS assay. Anal Biochem. 2009;392(1):37-44. 
[12] Ricchi P, Ammirabile M, Costantini S, Di Matola T, Spasiano A, Genna ML, Cinque P, 
Prossomariti L. Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis 
in patients with thalassemia intermedia: a retrospective study. Blood Cells Mol Dis. 
2012;49(3-4):133-5. 
[13] Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician. 
2004;69(11):2599-606. 
[14] Peluso I, Teichner A, Manafikhi H, Palmery M. Camellia Sinensis in Asymptomatic 
Hyperuricaemia: A Meta-analysis of Tea or Tea Extract Effects on Uric Acid Levels. Crit Rev 
Food Sci Nutr. 2017;57(2):391-398. 
[15] Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: 
comprehensive free software for meta-analysis of causal research data. BMC Med. Res. 
Methodol. 2006, 6, 50, doi:10.1186/1471-2288-6-50. 
[16] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6, e1000097. 
[17] Sengsuk C, Tangvarasittichai O, Chantanaskulwong P, Pimanprom A, Wantaneeyawong S, 
Choowet A, Tangvarasittichai S. Association of Iron Overload with Oxidative Stress, Hepatic 
Damage and Dyslipidemia in Transfusion-Dependent β-Thalassemia/HbE Patients. Indian J 
Clin Biochem. 2014;29(3):298-305.  
 14 
[18] Tangvarasittichai S, Pimanprom A, Choowet A, Tangvarasittichai O. Association of iron 
overload and oxidative stress with insulin resistance in transfusion-dependent beta-thalassemia 
major and beta-thalassemia/HbE patients. Clin Lab. 2013;59(7-8):861-8.  
[19] Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G, Cappellini MD. Oxidative status 
and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest. 2002;32(Suppl 1):55-60.  
[20] Pavlova LE, Savov VM, Petkov HG, Charova IP. Oxidative stress in patients with beta-
thalassemia major. Prilozi. 2007;28(1):145-54. 
[21] Al-Quobaili FA, Abou Asali IE. Serum levels of lipids and lipoproteins in Syrian patients with 
beta-thalassemia major. Saudi Med J. 2004;25(7):871-5. 
[22] Metwalley KA, El-Saied AR. Glucose homeostasis in Egyptian children and adolescents with 
β-Thalassemia major: Relationship to oxidative stress. Indian J Endocrinol Metab. 
2014;18(3):333-9. 
[23] Adhiyanto C, Hattori Y, Yamashiro Y, Mella F, Nitta T, Iihoshi M, Araki S, Matar M, Takagi 
F. Oxidation status of β-thalassemia minor and Hb H disease, and its association with glycerol 
lysis time (GLT50). Hemoglobin. 2014;38(3):169-72. 
[24] Asif M, Manzoor Z, Farooq MS, Munawar SH, Aziz A4, Khan IA. Status of oxidant, 
antioxidantand serum enzymes in thalassaemic children receiving multiple blood transfusions. 
J Pak Med Assoc. 2015;65(8):838-43. 
[25] Awadallah S, Al Arrayed K, Bahareth E, Saeed Z. Total antioxidant capacity and ischemia 
modified albumin in beta thalassemia. Clin Lab. 2013;59(5-6):687-91.  
[26] Bazvand F, Shams S, Borji Esfahani M, Koochakzadeh L, Monajemzadeh M, Ashtiani MT, 
Rezaei N. Total Antioxidant Status in Patients with Major β-Thalassemia. Iran J Pediatr. 
2011;21(2):159-65.  
[27] Cakmak A, Soker M, Koc A, Aksoy N. Prolidase activity and oxidative status in patients with 
thalassemia major. J Clin Lab Anal. 2010;24(1):6-11.  
 15 
[28] El Gendy WM, Mourad ZM, El Guiziry DA, Hassab HMA. Study of the Oxidative Stress in 
Thalassemia Alex J Pediatr. 1999;13(2):291-294. 
[29] Elsayh KI, Zahran AM, El-Abaseri TB, Mohamed AO, El-Metwally TH. Hypoxia Biomarkers, 
Oxidative Stress, and Circulating Microparticles in Pediatric Patients With Thalassemia in 
Upper Egypt. Clin Appl Thromb Hemost. 2013;20(5):536-545.  
[30] Ghone RA, Kumbar KM, Suryakar AN, Katkam RV, Joshi NG. Oxidative stress and 
disturbance in antioxidant balance in beta thalassemia major. Indian J Clin Biochem. 
2008;23(4):337-40.  
[31] Gunay A, Dogru AD, Isik B, Soker M, Gunay A. Investigation of periodontal parameters, total 
antioxidant status and ferritin levels in patients with thalassemia major. J Int Dental Medical 
Research 2015;8(1):15-20.  
[32] Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: 
relation to chelation therapy: original prospective study. Ital J Pediatr. 2010;36:39.  
[33] Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, 
Miled A. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin 
Chim Acta. 2003;338(1-2):79-86.  
[34] Kuppusamy UR, Tan JAMA. Chelation Therapy with Desferrioxamine does not Normalize 
Ferritin Level but Attenuates Oxidative Damage and Improves Total Antioxidant Level in 
Malaysian Chinese β-thalassaemia Major Patients. West Indian Med J 2011;60 (1): 3-8. 
[35] Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, D'Arpa D, 
D'Anna R, Bongiorno A. Oxidative stress and antioxidant status in beta-thalassemia major: 
iron overload and depletion of lipid-soluble antioxidants. Blood. 1996;88(9):3608-14. 
[36] Mastroiacovo P, Peluso I, Dante D, Martino F, Agolini D, Perla FM. Plasma red-ox status in 
β-thalassemic subjects. J Food Sci. Nutr. 1999;3:271-275. 
[37] Ozdem S, Kupesiz A, Yesilipek A. Plasma homocysteine levels in patients with beta-
thalassaemia major. Scand J Clin Lab Invest. 2008;68(2):134-9.  
 16 
[38] Ozdemir ZC, Koc A, Aycicek A, Kocyigit A. N-acetylcysteine supplementation reduces 
oxidative stress and DNA damage in children with β-thalassemia. Hemoglobin. 
2014;38(5):359-64. 
[39] Labib HA, Etewa RL, Gaber OA, Atfy M, Mostafa TM, Barsoum I. Paraoxonase-1 and 
oxidative status in common Mediterranean β-thalassaemia mutations trait, and their relations 
to atherosclerosis. J Clin Pathol. 2011;64(5):437-42.  
[40] Ondei Lde S, Estevão Ida F, Rocha MI, Percário S, Souza DR, Pinhel MA, Bonini-Domingos 
CR. Oxidative stress and antioxidant status in beta-thalassemia heterozygotes. Rev Bras 
Hematol Hemoter. 2013;35(6):409-13.  
[41] Palasuwan A, Kittisakulrat T, Amornrit W, Soogarun S, Wiwanitkit V, Pradniwat P. 
Antioxidant in plasma of hemoglobin-E trait. Southeast Asian J Trop Med Public Health. 
2005;36(S4):271-3.  
[42] Palasuwan A, Soogarun S, Suksom D, Pitaksathienkul C, Rousseau AS.Antioxidant status in 
haemoglobin E carriers after acute and chronic strenuous exercises. Res Sports Med. 
2015;13:1-16.  
[43] Selek S, Aslan M, Horoz M, Gur M, Erel O. Oxidative status and serum PON1 activity in 
beta-thalassemia minor. Clin Biochem. 2007;40(5-6):287-91. 
[44] Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement 
of antioxidant activity in human fluids. J Clin Pathol. 2001;54(5):356-61. 
[45] Ghiselli A, Serafini M, Maiani G, Azzini E, Ferro-Luzzi A. A fluorescence-based method for 
measuring total plasma antioxidant capability. Free Radic Biol Med. 1995;18(1):29-36. 
[46] Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant 
power": the FRAP assay. Anal Biochem. 1996;239(1):70-6. 
[47] Lissi E, Salim-Hanna M, Pascual C, del Castillo MD. Evaluation of total antioxidant potential 
(TRAP) and total antioxidant reactivity from luminol-enhanced chemiluminescence 
measurements. Free Radic Biol Med. 1995;18(2):153-8. 
 17 
[48] Nagler RM, Klein I, Zarzhevsky N, Drigues N, Reznick AZ. Characterization of the 
differentiated antioxidant profile of human saliva. Free Radic Biol Med. 2002;32(3):268-77. 
[49] Benkhai H, Lemanski S, Below H, Heiden JU, Below E, Lademann J, Bornewasser M, Balz T, 
Chudaske C, Kramer A. Can physical stress be measured in urine using the parameter 
antioxidative potential? GMS Krankenhhyg Interdiszip. 2010;5(2). doi: 10.3205/dgkh000146 
[50] Duplancic D, Kukoc-Modun L, Modun D, Radic N. Simple and rapid method for the 
determination of uric acid-independent antioxidant capacity. Molecules. 2011;16(8):7058-68. 
[51] Malliaraki N, Mpliamplias D, Kampa M, Perakis K, Margioris AN, Castanas E. Total and 
corrected antioxidant capacity in hemodialyzed patients. BMC Nephrol. 2003;4:4. 
[52] Bentley R, Neuberger A. The mechanism of the action of uricase. Biochem J. 1952;52:694–
699. 
[53] Kirschbaum B. Total urine antioxidant capacity. Clin Chim Acta. 2001;305(1-2):167-73. 
[54] Rodrigues SL, Baldo MP, Capingana P, Magalhães P, Dantas EM, Molina Mdel C, Salaroli 
LB, Morelato RL, Mill JG. Gender distribution of serum uric acid and cardiovascular risk 
factors: population based study. Arq Bras Cardiol. 2012;98(1):13-21. 
[55] Zhang ML, Gao YX, Wang X, Chang H, Huang GW. Serum uric acid and appropriate cutoff 
value for prediction of metabolic syndrome among Chinese adults. J Clin Biochem Nutr 
2013;52(1):38-42. 
[56] Kawamoto R, Tabara Y, Kohara K, Kusunoki T, Abe M, Miki T. Serum uric acid is more 
strongly associated with impaired fasting glucose in women than in men from a community 
dwelling population. PLoS One 2013;8(6):e65886. 
[57] Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and 
nonalcoholic fatty liver disease. J Korean Med Sci 2011;26(3):386-91.  
[58] Emmerson BT. The management of gout. N Engl J Med. 1996;334(7):445-51. 
 18 
[59] Peluso I, Manafikhi H, Reggi R, Palmery M. Effects of red wine on postprandial stress: 
potential implication in non-alcoholic fatty liver disease development. Eur J Nutr. 
2015;54(4):497-507.  
[60] Peluso I, Palmery M. Risks of misinterpretation in the evaluation of the effect of fruit-based 
drinks in postprandial studies. Gastroenterol Res Pract. 2014;2014:870547. doi: 
10.1155/2014/870547. 
 19 
 
Figure legends 
Figure 1: Four-phase flow diagram of systematic review and meta-analysis. 
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Figure 2. Trim-and-fill funnel plot of BTM (A) and BTT or BTE (B). The solid circles represent 
actual identified studies, whereas the open circle in (B) represents the imputed study from a trim-
and-fill analysis. The imputed study causes a shift in the mean difference (MD). Trim-and-fill 
funnel plot of BTM (C) and BTT or BTE (D) after the exclusion of the study imputed of bias [28]. 
 
Table 1. Meta-analysis  
First author  
Year [reference] 
Dataset, BT type (comorbidity) Method 
Input summary 
MD (95% CI) 
p Weight (%) 
N° of 
studies 
(Datasets) 
Cumulative  
Meta-analysis  
MD (95% CI) 
Asif 2015 [24] 1, BTM TEAC +0.23 (+0.17 +0.29) <0.001 5.35%   
Awadallah 2013 [25] 2, BTM  TEAC -0.08 (-0.12 -0.03) 0.001 5.37% 2 (1, 2) +0.07 (-0.22 +0.38) 
Bazvand 2011 [26] 3, BTM M(a) TEAC +0,16 (+0.06 + 0.25) <0.001 5.25% 3 (1-3) +0.10 (-0.11 +0.32) 
Bazvand 2011 [26] 4, BTM F(b) TEAC +0.13 (+ 0.05 +0.21) <0.01 5.29% 4 (1-4) +0.11 (-0.05 +0.27) 
Cakmak 2010 [27] 5, BTM TEAC  -0.03 (-0.16 +0.09) 0.65 5.13% 5 (1-5) +0.08 (-0.06 +0.22) 
Elsayh 2013 [29] 6, BTM(a)  TEAC -0.85 (-1.09 -0.63) <0.001 4.61% 6 (1-6) -0.04 (-0.22 +0.13) 
Elsayh 2013 [29] 7, BTM+splenectomy(b) TEAC -0.94 (-1.18 -0.69) <0.001 4.51% 7 (1-7) -0.16 (-0.35 +0.03) 
Ghone 2008 [30] 8, BTM FRAP -0.60 (-0.65 -0.55) <0.001 5.36% 8 (1-8) -0.23 (-0.49 +0.03) 
Gunay 2015 [31] 9, BTM(a)  TEAC -0.13 (-0.26 +0.01) 0.06 5.10% 9 (1-9) -0.22 (-0.46 +0.02) 
Gunay 2015 [31] 10, BTM+gingivitis(b) TEAC -0.14 (-0.27 -0.01) <0.05 5.10% 10 (1-10) -0.21 (-0.44 + 0.01) 
Hamed 2010 [32] 11, BMT(a)  ELISA -0.25 (-0.34 -0.15) <0.001 5.25% 11 (1-11) -0.21 (-0.42 -0.01) 
Hamed 2010 [32] 12, BTM+chelation(b) ELISA -0.20 (-0.29 -0.10) <0.001 5.26% 12 (1-12) -0.21 (-0.40 -0.02) 
Kassab-Chekir 2003 [33] 13, BTM TRAP -1.01 (-1.22 -0.79) <0.001 4.70% 13 (1-13) -0.27 (-0.46 -0.08) 
Kuppusamy 2011 [34] 14, BMT(a)  FRAP -0.17 (-0.37 +0.02) 0.07 4.81% 14 (1-14) -0.26 (-0.44 -0.08) 
Kuppusamy 2011 [34] 15, BTM+chelation(b) FRAP +0.03 (-0.09 +0.15) 0.63 5.17% 15 (1-15) -0.24 (-0.41 -0.07) 
Livrea 1996 [35] 16, BTM (6IDDM, 6CVD, 31HCV+) TEAC -0.17 (-0.22 -0.12) <0.001 5.36% 16 (1-16) -0.24 (-0.39 -0.09) 
Mastroiacovo 1999 [36] 17, BTM(a)  TRAP -0.02 (-0.15 +0.10) 0.70 5.15% 17 (1-17) -0.22 (-0.37 -0.08) 
Mastroiacovo 1999 [36] 18, BMT infected (b)  TRAP -0.20 (-0.39 -0.01) <0.05 4.80% 18 (1-18) -0.22 (-0.36 -0.08) 
Ozdem 2008 [37] 19, BTM TEAC -0.22 (-0.30 -0.13) <0.001 5.29% 19 (1-19) -0.22 (-0.35 -0.09) 
Ozdemir 2014 [38] 20, BTM  TEAC -0,27 (-0.74 +0.20) 0.26 3.14% 20 (1-20) -0.22 (-0.35 -0.09) 
Overall BTM  -0.22 (-0.35 -0.09) <0.001 100%   
        
Labib 2011 [39] 1, BTT UAEAC -0.67 (-0.85 -0.49) <0.001 18.42%   
Ondei 2013 [40] 2, BTT TEAC + 0,11 (+0.07 + 0.15) <0.001 21.11% 2 (1, 2) -0.27 (-1.04 +0.49) 
Palasuwan 2005 [41] 3, BTE TEAC -0.16 (-0.28 -0.05) <0.01 19.97% 3 (1-3) -0.23 (-0.62 +0.15) 
Palasuwan 2015 [42] 4, BTE TEAC -0.28 (-0.41 -0,15) <0,001 19.59% 4 (1-4) -0.24 (-0.55 +0.07) 
Selek 2007 [43] 5, BTT TEAC -0.15 (-0.21 -0.09) <0.001 20.91% 5 (1-5) -0.22 (-0.44 -0.01) 
Overall  BTT/BTE  -0.22 (-0.44 -0.01) <0.05 100%   
Random Effects estimate in BTM and BTT or BTE. MD: mean difference. CI 95%: confidence intervals 95%. 
BT: beta-thalassemia; BTE: Hemoglobin E talassemia; BTM: beta-thalassemia major; BTT: beta-thalassemia Trait (or minor); F: females; FRAP: Ferric Reducing Antioxidant 
Potential (μmol Fe+2 equiv./l); HCV+: hepatitis C virus positive;  HIV+: human immunodeficiency virus positive; M: males; TEAC: Trolox Equivalent Antioxidant Capacity 
(mmolTrolox Equiv./l); TRAP: Total-radical Trapping Antioxidant Parameter; UA: uric acid; UAEAC: μmol UAequiv./l.  
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Table 2. Characteristics of the included case-control studies.  
First author  
Year [reference] 
Study country Ethnicity 
Healthy n  
(age years) 
Disease n  
(age years) 
BT type 
(comorbidity) 
TAC 
(method) 
Other redox 
Markers 
Asif  2015 [24] Pakistan Asian 90 (1-10) 90 (1-10) BTM ↑ (TEAC) 
TOS, MDA, CAT↑ 
GPX↓ 
Awadallah 2013 [25] 
United Arab 
Emirates 
Middle-Eastern 43 (23.86.4) 55 (21.65.7) BTM (5% HCV+) ↓ (TEAC) BR↑ 
Bazvand 2011 [26] Iran Middle-Eastern 
66 (34a/32b) 
(15.17.3) 
66 (34a/32b) 
 (14.76.9) 
BTM M(a) 
BTM F(b) 
↑ (TEAC) 
BR, UA↑ 
TACcal↑ 
Cakmak 2010 [27] Turkey Middle-Eastern 33 (8.63.3) 87 (7.54.3) BTM ↔ (TEAC)  TOS↑ 
Elsayh 2013 [29] Egypt Middle-Eastern 46 (7.90.6) 
56 (32a/24b) 
(8.70.6) 
BTM(a) 
BTM+splenectomy(b) 
↓ (TEAC) 
ROOH ↔ 
MDA↑ 
Ghone 2008 [30] India Asian 72 (7-12) 72 (7-12) BTM ↓ (FRAP) 
MDA↑ 
Vit. E, SOD ↔  
Gunay 2015 [31] Turkey Middle-Eastern 25 (11-16) 
48 (25a+23b) 
 (11-16) 
BTM(a)  
BTM+gingivitis(b) 
↓ (TEAC)  
Hamed 2010 [32] Egypt Middle-Eastern 15 (8.44.1) 
69 (34a+b35)  
(8.73.7) 
BMT(a)  
BTM+chelation(b) 
↓ (ELISA) 
MDA↑  
UA↑ 
Kassab-Chekir  
2003 [33] 
Tunesia Middle-Eastern 51 (10.62.4) 56 (8.03.4) BTM  ↓ (TRAP)  
TBARS, SOD, GPX, BR↑ 
Vit. E, UA ↓ 
Kuppusamy 2011 
[34] 
Malaysia  Asian1 20 (15.06.0) 
39(6°+33b) 
(10.05.0, 
8.02.0) 
BMT(a) 
BTM+chelation(b) 
↓ (a) 
↔ (b)  
(FRAP) 
BR↑ (a)  
CAT-RBC ↔  
ROOH, CAT- PBMC ↑ 
GPX-RBC ↓  
GPX-PBMC ↓ (b) 
Livrea 1996 [35] Italy Caucasian 35 (29.05.0) 42 (21.010.0) 
BTM  
(6IDDM, 6CVD,  
31HCV+) 
↓ (TEAC) 
MDA, dienes, carbonyls, UA, 
BR↑ 
Vit. C, Vit, E, -car., Licopene, 
SH ↓ 
GSH ↔ 
Mastroiacovo 1999 
[36] 
Italy Caucasian 33 (17.5, 8-33) 
33 (26a+7b) 
(17.6, 8-33) 
BTM(a) 
BMT infected (b) 
(3HCV+, 3HIV+, 
1HCV+/HIV+)  
↓ (TRAP) 
UA ↔ 
BR, SH ↑  
Vit. C, VIT. E, -car., 
TRAPcal↓ 
Ozdem 2008 [37] Turkey Middle-Eastern 27 (17.09.0) 32 (18.08.0) BTM ↓ (TEAC)  
Ozdemir 2014 [38] Turkey Middle-Eastern 25 (8.03.8) 25 (8.6±4.1) BTM ↔ (TEAC)  TOS↑ 
Labib 2011 [39] Egypt Middle-Eastern 20 (38.18.3) 60 (36.67.9) BTT ↓ (UAEAC) MDA↑ 
Ondei 2013 [40] Brazil Caucasian2 81 (18-62) 49 (18-79) BTT ↑ (TEAC) TBARS↑ 
Palasuwan 2005 [41] Thailand Asian 171 (38.217.0) 14 (25.813.9) BTE ↓ (TEAC)   
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Palasuwan 2015 [42] Thailand Asian 10 (21.40.5) 10 (21.20.6) BTE ↓ (TEAC) SOD, GPX, TBARS ↔ 
Selek 2007 [43] Turkey Middle-Eastern 28 (27.04.9) 32 (28.02.0) BTT ↓ (TEAC) TOS, ROOH ↑ 
1 All Chinese; 2 Patients 100%, Controls 74%; -Car.: -Carotene; BR: bilirubin; BT: beta-thalassemia; BTE: Hemoglobin E talassemia; BTM: beta-thalassemia major; BTT: 
beta-thalassemia Trait (or minor); CAT: catalase; F: females; FRAP: Ferric Reducing Antioxidant Potential (μmol Fe+2 equiv./l); GPX: glutathione peroxidise; GSH: glutathione; 
HCV+: hepatitis C virus positive;  HIV+: human immunodeficiency virus positive; M: males; MDA: malonyldialdehyde; n: number of subjects; PBMC: Peripheral Blood 
Mononuclear Cells; RBC: Red Blood Cells; ROOH: peroxides; SH: thiols; SOD: superoxide dismutase; TAC: Total Antioxidant Capacity; TACcal: calculated TAC; TBARS: 
thiobarbituric acid reactive substances; TEAC: Trolox Equivalent Antioxidant Capacity (mmolTrolox Equiv./l); TOS: μmol H2O2 equiv./l; TRAP: Total-radical Trapping 
Antioxidant Parameter; TRAPcal: calculated TRAP; UA: uric acid; UAEAC: μmol UAequiv./l; Vit.: vitamin.  
 
 
 
